Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus Hompesch

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Diabetes Technology & Therapeutics|October 14, 2009
Capillary and venous blood glucose concentrations measured during intravenous insulin and glucose infusion: a comparison of steady and dynamic statesKirsten Kempe, David Price, John Ellison, et al.
Journal of Diabetes Science and Technology|July 5, 2011
Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulinLutz Heinemann, Marcus Hompesch, Frank Flacke, et al.
Clinical Pharmacology and Therapeutics|March 8, 2024
A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or DapagliflozinPablo Lapuerta, Silvia Urbina, Jiaojuan He, et al.
Clinical Pharmacology and Therapeutics|April 7, 2022
A Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Insulin DimerGeoffrey A Walford, Kelly E Duncan, Moises Hernandez, et al.
BMJ Open Diabetes Research & Care|June 26, 2021
Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib studyMarcus Hompesch, Jahoon Kang, OakPil Han, et al.
Diabetes, Obesity & Metabolism|March 17, 2020
Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetesKun-Ho Yoon, Jahoon Kang, Se Chang Kwon, et al.
Diabetes Care|September 15, 2018
Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover StudyMatthew C Riddle, Rajaa Nahra, Jenny Han, et al.
Journal of Diabetes Science and Technology|November 4, 2009
Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulinMarcus Hompesch, Laura McManus, Roderike Pohl, et al.
Plos One|October 1, 2014
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetesSue Sha, Damayanthi Devineni, Atalanta Ghosh, et al.
Current Medical Research and Opinion|September 19, 2009
Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetesMarcus Hompesch, Scott M Ocheltree, Eshetu T Wondmagegnehu, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Diabetes Technology & Therapeutics|October 14, 2009
Capillary and venous blood glucose concentrations measured during intravenous insulin and glucose infusion: a comparison of steady and dynamic statesKirsten Kempe, David Price, John Ellison, et al.
Journal of Diabetes Science and Technology|July 5, 2011
Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulinLutz Heinemann, Marcus Hompesch, Frank Flacke, et al.
Clinical Pharmacology and Therapeutics|March 8, 2024
A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or DapagliflozinPablo Lapuerta, Silvia Urbina, Jiaojuan He, et al.
Clinical Pharmacology and Therapeutics|April 7, 2022
A Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Insulin DimerGeoffrey A Walford, Kelly E Duncan, Moises Hernandez, et al.
BMJ Open Diabetes Research & Care|June 26, 2021
Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib studyMarcus Hompesch, Jahoon Kang, OakPil Han, et al.
Diabetes, Obesity & Metabolism|March 17, 2020
Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetesKun-Ho Yoon, Jahoon Kang, Se Chang Kwon, et al.
Diabetes Care|September 15, 2018
Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover StudyMatthew C Riddle, Rajaa Nahra, Jenny Han, et al.
Journal of Diabetes Science and Technology|November 4, 2009
Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulinMarcus Hompesch, Laura McManus, Roderike Pohl, et al.
Plos One|October 1, 2014
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetesSue Sha, Damayanthi Devineni, Atalanta Ghosh, et al.
Current Medical Research and Opinion|September 19, 2009
Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetesMarcus Hompesch, Scott M Ocheltree, Eshetu T Wondmagegnehu, et al.
Pageof 6